TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03527186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM® 100 mg
Description: 100 mg of risperidone ISM® administered every 4 weeks
Study: NCT01755338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 15mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03587467

Intervention type: OTHER
Intervention: collect fecal specimens
Description: collect fresh fecal specimens of participants

Intervention type: OTHER
Intervention: collect fecal specimens
Description: collect fresh fecal specimens of participants

Intervention type: OTHER
Intervention: collect fecal specimens
Description: collect fresh fecal specimens of participants

Intervention type: OTHER
Intervention: collect fecal specimens
Description: collect fresh fecal specimens of participants
Study: NCT03644381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy
Description: Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
Study: NCT00675688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugate Estrogens (CE)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02943668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02773472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.

Intervention type: DRUG
Group type: OTHER
Intervention: morphine
Description: Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
Study: NCT00425945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pine Bark Extract (Flavangenol®)
Description: Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pine Bark Extract (Flavangenol®)
Description: Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks.
Study: NCT04389268

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Event-Related Potentials
Description: Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Event-Related Potentials
Description: Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
Study: NCT00878306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: 62.5 mg daily x3 days, then 250 mg daily x3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram + Efavirenz
Description: Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram + Atazanavir
Description: Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram + Ritonavir
Description: Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Study: NCT02195947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
Study: NCT01099761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 0.5 mg/kg q4wk
Description: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 1.0 mg/kg q2wk
Description: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
Study: NCT02803814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior mesenteric artery approach for pancreatoduodenectomy
Description: Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic approach for pancreatoduodenectomy
Description: Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
Study: NCT02090673

Intervention type: DRUG
Intervention: Exenatide
Study: NCT04533516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy technics
Description: Manual therapy technics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training
Study: NCT02550119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolasetron Mesylate
Description: Given PO or IV
Study: NCT00866190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
Study: NCT04663698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated Resistor 11
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated Resistor 11
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated Resistor 11
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
Study: NCT04291638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Caregiver Training
Description: The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Caregiver Training
Description: The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Intensive Group Behavioral Treatment (IGBT)
Description: The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
Study: NCT02550119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dolasetron Mesylate
Description: Given PO or IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT04192318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging the Gap
Description: Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
Study: NCT03000595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN007 Cream
Description: A cream containing 5% East Indian sandalwood oil (EISO).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The vehicle cream
Study: NCT02531841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
Description: Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
Description: 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \* if carmustine is not available at the investigation site, busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)
Study: NCT01526954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TissuGlu Surgical Adhesive
Description: TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
Study: NCT03822520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Pure water 150ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Pure water 150ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Pure water 150ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Pure water 150ml
Study: NCT02378922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene-Modified HIV-Protected Hematopoietic Stem Cells
Description: Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transplant Conditioning
Description: Undergo high-dose chemotherapy or chemoradiotherapy
Study: NCT03865199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Intervention
Description: Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported.
Study: NCT04192318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communities that Care (CTC)
Description: In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communities that Care (CTC)
Description: In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treat and release

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treat and release
Study: NCT01171313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP21279 and carbidopa (experimental)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
Study: NCT00124735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bolus maintenance
Description: Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium continuous infusion maintenance
Description: Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
Study: NCT03572803

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group of Dry Needling
Description: Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group of Electrolysis
Description: Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
Study: NCT03576521

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CT + Ocoxin-Viusid
Description: The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: CT + Placebo
Description: The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center.
Study: NCT00772044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provent Professional Sleep Apnea Therapy Device
Description: Application of active device (Provent)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham device will be applied
Study: NCT01323686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging guided optimal LV lead placement
Description: LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate \<30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used.
Study: NCT01335828

Intervention type: DEVICE
Group type: OTHER
Intervention: Medical ultrasound device (ShearWave system)
Description: Echography (all modes) and elastography ShearWave system
Study: NCT02255877

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Surgical Skin Closure
Description: Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Surgical Skin Closure
Description: Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steel Staples
Description: Skin Closure device for the closure of the skin layer for surgical incisions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steel Staples
Description: Skin Closure device for the closure of the skin layer for surgical incisions.
Study: NCT01739244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL040012
Description: Ocular topical administration of SYL040012 for 14 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL040012
Description: Ocular topical administration of SYL040012 for 14 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL040012
Description: Ocular topical administration of SYL040012 for 14 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ocular topical administration of placebo for 14 consecutive days
Study: NCT04657172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic
Description: Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic
Description: Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle ophthalmic solution administered with the Optejet microdose dispenser
Study: NCT02724956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Description: Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
Study: NCT02515188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propacetamol
Description: Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
Study: NCT02545452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole / Levonorgestrel (BAY98-7196)
Description: Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole / Levonorgestrel (BAY98-7196)
Description: Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole / Levonorgestrel (BAY98-7196)
Description: Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole / Levonorgestrel (BAY98-7196)
Description: Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gyno-Daktarin
Description: 400 mg miconazole nitrate per day for 3 consecutive days
Study: NCT00866190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
Study: NCT02545452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sobelin vaginal creme
Description: 100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patentex oval
Description: 75 mg Nonoxynol-9 per day for 3 consecutive days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tampon